The FDA has informed Icelandic biosimilars developer Alvotech that it must address issues found in the March 2022 preapproval inspection of the company’s Reykjavik manufacturing facility before the agency will consider final approval of the Biologics License Application (BLA) for AVTOC2, a biosimilar to AbbVie’s Humira (adalimumab).
Source: Drug Industry Daily